ProQR Therapeutics (PRQR) Current Deferred Revenue (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Current Deferred Revenue for 5 consecutive years, with $20.4 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 12.86% to $20.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.4 million through Dec 2025, down 12.86% year-over-year, with the annual reading at $20.4 million for FY2025, 12.86% down from the prior year.
  • Current Deferred Revenue hit $20.4 million in Q4 2025 for ProQR Therapeutics, down from $23.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $23.4 million in Q4 2024 to a low of $5.8 million in Q4 2022.
  • Historically, Current Deferred Revenue has averaged $15.5 million across 5 years, with a median of $20.4 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 284.54% in 2023 and later dropped 12.86% in 2025.
  • Year by year, Current Deferred Revenue stood at $5.9 million in 2021, then decreased by 1.64% to $5.8 million in 2022, then surged by 284.54% to $22.1 million in 2023, then grew by 5.95% to $23.4 million in 2024, then fell by 12.86% to $20.4 million in 2025.
  • Business Quant data shows Current Deferred Revenue for PRQR at $20.4 million in Q4 2025, $23.4 million in Q4 2024, and $22.1 million in Q4 2023.